Corrigendum to ‘Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)’
Year: 2020
Type: erratum
Source: Annals of Oncology
Institutions: Banner MD Anderson Cancer Center, Universidad San Pablo CEU, Tennessee Oncology, TUM Klinikum, Technical University of Munich, Marqués de Valdecilla University Hospital, Cancer Treatment Centers of America, Royal Marsden Hospital, Charité – Universitätsmedizin Berlin, Merrimack Pharmaceuticals (United States), University of California, San Francisco, University of California San Francisco Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Gilead Sciences, Celgene, Array BioPharma, Novocure, Five Prime Therapeutics, Agios Pharmaceuticals, Unum Therapeutics, BeiGene, Incyte, Calithera Biosciences, NGM Biopharmaceuticals, Revolution Medicines, Moderna, MacroGenics, Eisai, Genentech, EMD Serono, Takeda Oncology, Daiichi Sankyo Europe
OpenAlex ID: W4246059218